Rocio I. Pereira

Rocio I. Pereira

Auto-generated profile, based on publicly available information

Rocio I. Pereira

Department of Medicine, Denver Health, Denver, Colorado

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2022 in Diabetes Care
Verified
Journal Article
Open access
PDF file
KNKevin Ni
Kevin Ni
CTCarolyn A. Tampe
Carolyn A. Tampe
KSKayce Sol
Kayce Sol
DRDouglas B. Richardson
Douglas B. Richardson
RPRocio I. Pereira
Rocio I. Pereira
OBJECTIVE: Current studies on continuous glucose monitor (CGM) uptake are revealing for significant barriers and inequities for CGM use among patients from socially underprivileged communities. This study explores the effect of full subsidies regardless of diabetes type on CGM uptake and HbA1c outcomes in a U.S. adult patient population on Medicaid. RESEARCH DESIGN AND METHODS: This retrospective cohort study examined 3,036 adults with diabetes enrolled in a U.S. Medicaid program that fully subsidized CGM. CGM uptake and adherence were assessed by CGM prescription and dispense data, including more than one fill and adherence by medication possession ratio (MPR). Multivariate logistic regression evaluated predictors of CGM uptake. Pre- and post-CGM use HbA1c were compared. RESULTS: CGM were very well received by both individuals with type 1 diabetes and individuals with type 2 diabetes with similar high fill adherence levels (mean MPR 0.78 vs. 0.72; P = 0.06). No significant difference in CGM uptake outcomes were noted among major racial/ethnic groups. CGM use was associated with improved HbA1c among those with type 2 diabetes (−1.2% [13.1 mmol/mol]; P < 0.001) that was comparable between major racial/ethnic groups and those with higher fill adherence achieved greater HbA1c reduction (−1.4% [15.3 mmol/mol]; P < 0.001) compared with those with lower adherence (−1.0% [10.9 mmol/mol]; P < 0.001). CONCLUSIONS: CGM uptake disparities can largely be overcome by eliminating CGM cost barriers. CGM use was associated with improved HbA1c across all major racial/ethnic groups, highlighting broad CGM appeal, utilization, and effectiveness across an underprivileged patient population.

10 August 2023 in Diabetes Care
Verified
Journal Article
Open access
PDF file
EFErin Finn
Erin Finn
LSLindsay Schlichting
Lindsay Schlichting
LGLaura Grau
Laura Grau
IDIvor S. Douglas
Ivor S. Douglas
RPRocio I. Pereira
Rocio I. Pereira
OBJECTIVE: We sought to determine real-world accuracy of inpatient continuous glucose monitoring (CGM) at multiple levels of acuity in a large safety-net hospital. RESEARCH DESIGN AND METHODS: We analyzed records from hospitalized patients on Dexcom G6 CGM, including clinical, point of care (POC), and laboratory (Lab) glucose, and CGM data. POC/Lab values were matched to the closest timed CGM value. Encounters were divided into not critically ill (NCI) versus critically ill (CI). CGM accuracy was evaluated. RESULTS: Paired readings (2,744 POC-CGM; 3,705 Lab-CGM) were analyzed for 233 patients with 239 encounters (83 NCI, 156 CI). POC-CGM aggregated and average mean absolute relative differences (MARD) were 15.1% and 17.1%. Lab-CGM aggregated and average MARDs were 11.4% and 12.2%. Accuracy for POC-CGM and Lab-CGM was 96.5% and 99.1% in Clarke Error Grid zones A/B. CONCLUSIONS: Real-world accuracy of inpatient CGM is acceptable for NCI and CI patients. Further exploration of conditions associated with lower CGM accuracy in real-world settings is warranted.

18 September 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
TITalat Alp Ikizler
Talat Alp Ikizler
HKHolly J. Kramer
Holly J. Kramer
SBSrinivasan Beddhu
Srinivasan Beddhu
ACAlex Chang
Alex Chang
AFAllon N. Friedman
Allon N. Friedman
FDfor the ASN Kidney Health Guidance Workgroup on Obesity and Kidney Diseases
for the ASN Kidney Health Guidance Workgroup on Obesity and Kidney Diseases

13 January 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
RDRuban Dhaliwal
Ruban Dhaliwal
RPRocio I Pereira
Rocio I Pereira
ADAlicia M Diaz-Thomas
Alicia M Diaz-Thomas
CPCamille Powe
Camille Powe
LCLicy L. Yanes Cardozo
Licy L. Yanes Cardozo
JJJoshua J Joseph
Joshua J Joseph
The Endocrine Society recognizes racism as a root cause of the health disparities that affect racial/ethnic minority communities in the United States and throughout the world. In this policy perspective, we review the sources and impact of racism on endocrine health disparities and propose interventions aimed at promoting an equitable, diverse, and just healthcare system. Racism in the healthcare system perpetuates health disparities through unequal access and quality of health services, inadequate representation of health professionals from racial/ethnic minority groups, and the propagation of the erroneous belief that socially constructed racial/ethnic groups constitute genetically and biologically distinct populations. Unequal care, particularly for common endocrine diseases such as diabetes, obesity, osteoporosis, and thyroid disease, results in high morbidity and mortality for individuals from racial/ethnic minority groups, leading to a high socioeconomic burden on minority communities and all members of our society. As health professionals, researchers, educators, and leaders, we have a responsibility to take action to eradicate racism from the healthcare system. Achieving this goal would result in high-quality health care services that are accessible to all, diverse workforces that are representative of the communities we serve, inclusive and equitable workplaces and educational settings that foster collaborative teamwork, and research systems that ensure that scientific advancements benefit all members of our society. The Endocrine Society will continue to prioritize and invest resources in a multifaceted approach to eradicate racism, focused on educating and engaging current and future health professionals, teachers, researchers, policy makers, and leaders.

27 June 2024 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
KNKevin Ni
Kevin Ni
CTCarolyn A Tampe
Carolyn A Tampe
KSKayce Sol
Kayce Sol
LCLilia Cervantes
Lilia Cervantes
RPRocio I Pereira
Rocio I Pereira
Context: The rise in continuous glucose monitor (CGM) use has been characterized by widening disparities between the least and most socially marginalized. Given access barriers, there is limited CGM patient experience information that is inclusive of those with type 2 diabetes mellitus from socially marginalized backgrounds. Objective: To understand the CGM usage experience in the primary care setting across a US Medicaid population with type 2 diabetes at federally qualified health centers. Methods: This qualitative study used semi-structured phone interviews with 28 English- or Spanish-speaking participants prescribed the CGM who were enrolled in a US Medicaid program that subsidized CGMs. Audio recordings of interviews were transcribed and analyzed by reflective thematic analysis. Results: Twenty-eight participants (75% female, median age 56 years with interquartile-range 48-60 years) were interviewed. Participants were from different racial/ethnic backgrounds: 21% non-Hispanic White, 57% Hispanic, and 18% non-Hispanic Black. Participants primarily spoke English (68%) or Spanish (32%), and 53% reported 9 or fewer years of formal education. We identified 6 major themes: initial expectations and overcoming initiation barriers, convenience and ease promote daily use, increased knowledge leads to improved self-management, collaboration with provider and clinical team, improved self-reported outcomes, and barriers and burdens are generally tolerated. Conclusion: CGM use was experienced as easy to understand and viewed as a tool for diabetes self-efficacy. Expanded CGM access for socially marginalized patients with type 2 diabetes can enhance diabetes self-management to help mitigate diabetes outcome disparities.

8 May 2021 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
RPRocio I. Pereira
Rocio I. Pereira
LCLilia Cervantes
Lilia Cervantes
Latinx communities comprise the largest ethnic/racial minority category in the United States, and, as a group, they have a disproportionately high burden of CKD and a faster progression to kidney failure compared with non-Latinx White individuals. These health disparities have been attributed to differences in clinical care and complex social challenges, which are largely modifiable. However, our health care system has been unsuccessful in addressing barriers to care for Latinx people, resulting in widening disparities in health outcomes, including those related to CKD. Culture- and language-concordant community-based approaches may reduce social challenges and the burden of CKD among Latinx individuals.